

EQA round: AP1/24 - Antithrombotic Agents

Deadline: 29.3.2024

Setup: groups - M (measurement principle); minimal size of the groups n = 5

RoM = robust average

SD = standard deviation

CV = coefficient of variation

N_{tot} = total number of the resultsN_{out} = number of the results removed before calculation

AV = assigned value

CVP = consensus of all participants

U_{AV} = expanded uncertainty of the assigned value (k = 2)D_{max} = acceptable difference

LL = lower limit

UL = upper limit

N_{eva} = number of the results assessedN_{suc} = number of successful resultsS_{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel} [%]	
							AV	U _{AV}	D _{max}	LL	UL					
Set 1																
(108) Apixaban	[µg/L]				44									44	42	95
Sample A1		68,3	6,6	9,7	44		CVP	68,3	2,4	25%	51,2	85,4		44	42	95
(2) Chromogenous substrat		68,6	6,8	9,9	40	0								40		
Other					4	0								4		
							4x 1									
Sample B1		285	20	7	44		CVP	285	7,4	25%	213	357		44	44	100
(2) Chromogenous substrat		283	18	6,5	40	0								40		
Other					4	0								4		
							4x 1									
Set 2																
(109) Dabigatran	[µg/L]				36									36	35	97
Sample A2		54,2	5,8	11	36		CVP	54,2	2,3	30%	37,9	70,5		36	36	100
(1) Coagulometer		55,1	7	13	21	0								21		
(2) Chromogenous substrat		53,5	4,7	8,8	15	0								15		
Sample B2		214	30	14	36		CVP	214	12	30%	149	279		36	35	97
(1) Coagulometer		216	37	17	21	0								21		
(2) Chromogenous substrat		210	10	4,9	15	0								15		
Set 3																
(110) Rivaroxaban	[µg/L]				48									48	47	98
Sample A3		77,1	5,5	7,2	48		CVP	77,1	2	25%	57,8	96,4		48	47	98
(2) Chromogenous substrat		77,2	5,8	7,5	45	0								45		
Other					3	0								3		
							3x 1									
Sample B3		304	21	7	48		CVP	304	7,6	25%	228	380		48	48	100
(2) Chromogenous substrat		304	22	7,2	45	0								45		
Other					3	0								3		
							3x 1									